Roche’s recent announcement regarding the Phase II clinical trial for CT-388, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has sparked excitement in the biotech community. The trial demonstrated significant weight loss outcomes, positioning CT-388 as a potential game-changer in obesity treatment.
Study Overview
The Phase II study, named CT388-103, involved a comprehensive evaluation of CT-388’s efficacy in promoting weight loss among adults with obesity or overweight conditions. The trial included 469 participants who were randomly assigned to receive either CT-388 at various dosages or a placebo.
Notably, participants received weekly subcutaneous injections, which highlighted the convenience of a once-weekly regimen. The results indicate that CT-388 led to substantial, sustained, and dose-dependent weight loss over a 48-week period, with minimal plateauing of results.
Efficacy Outcomes
The findings from CT388-103 were compelling. At the highest dose of 24 mg, participants experienced a placebo-adjusted mean weight reduction of 22.5% by week 48, demonstrating strong efficacy. For those following the treatment regimen estimand, the placebo-adjusted weight loss was 18.3%, achieving statistical significance with a p-value of less than 0.001.
The study revealed a clear dose-response relationship, with increased doses correlating with enhanced weight loss. Most notably, 95.7% of participants lost at least 5% of their body weight, while 87% achieved reductions of 10% or more. Furthermore, nearly half of the participants lost 20% or more, and 26.1% reached or exceeded a 30% reduction in body weight.
Metabolic Benefits
Beyond weight loss, the trial’s results indicated potential metabolic benefits, particularly for pre-diabetic participants. An impressive 73% of those with pre-diabetes achieved normal blood glucose levels by the end of the study, compared to only 7.5% in the placebo group. This suggests that CT-388 may offer additional advantages beyond weight management, enhancing its appeal in the market.
Safety Profile
The safety and tolerability profile of CT-388 aligned with expectations for medications within the incretin class. Participants generally tolerated the treatment well, further bolstering confidence in the drug’s future development. Roche’s Chief Medical Officer, Dr. Levi Garraway, expressed enthusiasm over the meaningful weight loss and the favorable safety profile, reinforcing the company’s commitment to advancing CT-388 into Phase III trials.
Path Forward
Roche is poised to continue its clinical development of CT-388. An additional Phase II study, CT388-104, is underway, targeting participants living with obesity or overweight who also suffer from type 2 diabetes. This trial aims to further assess the drug’s efficacy, safety, and tolerability in a slightly different patient population, potentially broadening its clinical utility.
Looking ahead, Roche plans to initiate its Phase III clinical program, named Enith1 and Enith2, for CT-388 in obesity during the first quarter of 2026. As the company progresses toward these pivotal trials, the anticipation within the biopharma community continues to grow.
Key Takeaways
- CT-388 demonstrated significant weight loss in a Phase II trial, with a placebo-adjusted mean reduction of 22.5% at the highest dose.
- The drug showed a favorable safety profile consistent with existing incretin therapies, supporting its further development.
-
The trial indicated potential metabolic benefits, with a significant percentage of pre-diabetic participants achieving normal blood glucose levels.
-
Roche plans to advance CT-388 into Phase III trials, with expectations set for early 2026.
In conclusion, Roche’s positive results from the CT388-103 trial mark a significant milestone in the search for effective obesity treatments. With promising efficacy and a well-tolerated safety profile, CT-388 could potentially reshape the landscape of obesity management, offering hope to millions struggling with weight-related health issues. The upcoming Phase III trials will be critical in determining the drug’s future and its place in therapeutic protocols.
Read more → www.pharmexec.com